Cargando…

1601. Combination Therapy versus Monotherapy for Carbapenem-resistant Organisms: Is More Really Better?

BACKGROUND: Carbapenem-resistant organisms (CROs) represent an urgent public health threat and associated with mortality rates up to 60%. Pharmacotherapy for these infections remain challenging and historically included multiple agents. Meropenem/vaborbactam and ceftazidime/avibactam are options to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Najia, Laila, Carr, Amy, Alexander, Jose, Minor, Sarah B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778249/ http://dx.doi.org/10.1093/ofid/ofaa439.1781

Ejemplares similares

P1601: THE ASSESSMENT OF PREDICTIVE ROLE OF PROTEIN C AND S FOR CRITICAL FORM OF COVID-19
por: Popov, V., et al.
Publicado: (2022)

Colistin monotherapy versus therapy combination
por: Charra, B, et al.
Publicado: (2010)

1601. Evaluation of Synergy with β-Lactams Plus Aztreonam Against Pseudomonas aeruginosa (PSA)
por: O’Donnell, J Nicholas, et al.
Publicado: (2019)

1601. Transmitted Drug Resistance in Treatment-Naïve People Living with HIV in Costa Rica
por: Ramirez-Cardoce, Manuel, et al.
Publicado: (2023)

P1601: PREDICTING THE RESPONSE TO SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA (ITP): A MULTI-CENTRIC PILOT STUDY
por: Zoletto, Simone, et al.
Publicado: (2023)

2130. Detection of Carbapenemase-Producing Organisms and Impact on Antimicrobial Utilization for Carbapenem-Resistant Enterobacteriaceae (CRE) Infections
por: Minor, Sarah Brooks, et al.
Publicado: (2019)

272. Clinical Outcomes with Continuation of Combination Antibiotic Therapy versus De-escalation to Monotherapy for Patients with MRSA Bacteremia
por: Nichols, Courtney, et al.
Publicado: (2020)

204. Clinical Outcomes with Ceftaroline Monotherapy versus Daptomycin-Ceftaroline Combination Therapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Andonie, Gabriela, et al.
Publicado: (2021)

1607. Dual Therapy with Aztreonam & Ceftazidime/Avibactam Against Multi-Drug Resistant Stenotrophomonas maltophilia on Tricuspid Valve Endocarditis
por: Alexander, Jose, et al.
Publicado: (2020)

1601 Screening for chronic obstructive pulmonary disease (COPD) in an urban HIV clinic
por: Shirley, Daniel, et al.
Publicado: (2014)

1601. Effect of Preemptive Rituximab Therapy on Epstein–Barr Reactivation in Allogenic Hematopoietic Stem Cell Pediatric Transplants
por: Catho, Gaud, et al.
Publicado: (2018)

Poor relief in England and Wales 1601–1834
Publicado: (1976)

Colistin Plus Carbapenem versus Colistin Monotherapy in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Pneumonia
por: Shi, HyeJin, et al.
Publicado: (2019)

1270. Early Real-world Evidence in the Use of Eravacycline for the Management of Draconian Infections
por: Carr, Amy, et al.
Publicado: (2020)

283. Population-Based Co-infection of Carbapenem-Resistant Organisms and SARS-CoV-2 in Massachusetts
por: Geoghegan, Ashley, et al.
Publicado: (2021)

Dosing Exercise: Is More Really Better for Obesity Related Outcomes?
por: Malin, Steven K.
Publicado: (2018)

The mathematical career of Pierre de Fermat: 1601-1665
por: Mahoney, Michael Sean
Publicado: (1994)

1441. Using Carbapenem Resistance Levels to Discriminate Between Carbapenemase Producing and Non-Carbapenemase Producing Carbapenem Resistant Enterobacteriaceae
por: Koehne, William J, et al.
Publicado: (2020)

1490. Serious Infections Caused by Carbapenem Susceptible and Carbapenem Resistant Acinetobacter baumannii-calcoaceticus Complex - A Retrospective Review
por: Rana, Khurram, et al.
Publicado: (2020)

211. A Comprehensive Assessment of Carbapenem Use across 90 Veterans Health Administration Hospitals with Defined Stewardship Strategies for Carbapenems
por: Suzuki, Hiroyuki, et al.
Publicado: (2020)

Is organic diet really necessary for children?
por: Vania, Andrea, et al.
Publicado: (2015)

304. Predictors of mortality in carbapenem-resistant Enterobacteriales bacteremia
por: Hovan, Michael R, et al.
Publicado: (2020)

John Clavell, 1601–43: highwayman, author, lawyer, doctor
por: Harley, David
Publicado: (1994)

1457. Serial Passage of Enterobacteriaceae to Explore Development of Carbapenem Resistance
por: Nissim, Yosef, et al.
Publicado: (2020)

Monotherapy versus Combination Therapy against Nonbacteremic Carbapenem-resistant Gram-negative Infections: A Retrospective Observational Study
por: Ghafur, Abdul, et al.
Publicado: (2017)

A randomized trial of combination therapy versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia
por: Heyland, D, et al.
Publicado: (2007)

848. Trends of Carbapenem Resistance in Enterobacterales in the US Between 2015 and 2019
por: Marcella, Stephen, et al.
Publicado: (2020)

223. Difference in Carbapenem Use by ASP Intervention in Japanese Healthcare Facilities
por: Endo, Mio, et al.
Publicado: (2020)

85. The Impact of Carbapenem-Sparing Interventions on the Evolution of Resistance in Pseudomonas aeruginosa in the USA
por: Townsend, Jeffrey, et al.
Publicado: (2020)

1055. ARGONAUT-IV: Susceptibility of Carbapenem-resistant Klebsiellae to Ceftibuten/VNRX-5236
por: Mack, Andrew R, et al.
Publicado: (2021)

Carbapenems versus alternative β-lactams monotherapy or in combination for febrile neutropenia: Systematic review and meta-analysis of randomized controlled trial
por: Tang, Xiuge, et al.
Publicado: (2020)

Combination Regimens with Colistin Sulfate versus Colistin Sulfate Monotherapy in the Treatment of Infections Caused by Carbapenem-Resistant Gram-Negative Bacilli
por: Hao, Min, et al.
Publicado: (2022)

199. Short versus Extended Antibiotic Treatment with a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients with Fever of Unknown Origin: A Randomized Multicenter Noninferiority Trial
por: de Jonge, Nick A, et al.
Publicado: (2020)

785. Distribution and Associated Mortality in Carbapenem-Resistant Gram-Negative Bacilli in Japan: A Multicenter Study From Multi-Drug Resistant Organisms Clinical Research Network (MDRnet)
por: Saito, Sho, et al.
Publicado: (2021)

Survival of carbapenem-resistant Acinetobacter baumannii bacteremia: colistin monotherapy versus colistin plus meropenem
por: Park, So Yeon, et al.
Publicado: (2019)

1618. Meropenem-vaborbactam vs standard of care for multidrug resistant carbapenem-resistant Enterobacteriaceae
por: Misikir, Helina, et al.
Publicado: (2020)

158. Intra- and Inter-hospital Epidemiology of Carbapenem-resistant klebsiella Pneumoniae in US Hospitals
por: Luterbach, Courtney, et al.
Publicado: (2020)

187. Significant Decline in Carbapenem Use with Multifaceted Antimicrobial Stewardship Program (ASP) Interventions
por: Kaushik, Ashlesha, et al.
Publicado: (2020)

P40 Kitchen sponges—home sweet home for carbapenem-resistant Klebsiella spp.
por: Debergh, H., et al.
Publicado: (2022)

Is LESS really more?
por: Graversen, Joseph A., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_3elejrcl027o1e4gpp49hsfd3t